Physician profile
Randall A Lee
NPI 1124023072
$1,180.72
in general payments reported to CMS, 2019-2025
20 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $327 · 2023: $24.05 · 2024: $581 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $327.44 | 2022 | |
| Novo Nordisk INC | $144.54 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $130.53 | 2024-2025 | |
| Lilly USA, LLC | $84.24 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $75.67 | 2024 | Gardasil 9, Gardasil, Vaxelis |
| Ironshore Pharmaceuticals INC. | $48.73 | 2024 | |
| Collegium Pharmaceutical, INC. | $47.16 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $43.79 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $43.72 | 2024-2025 | Farxiga |
| Dexcom, INC. | $30.37 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $29.99 | 2024-2025 | Repatha, Otezla, Repatha |
| Corium, LLC | $25.46 | 2025 | Azstarys |
| Hologic Sales and Service, LLC | $24.05 | 2023 | Myosure Tissue Removal Device |
| Seqirus USA INC | $20.15 | 2025 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $20.14 | 2024 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $19.16 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $17.60 | 2024 | Qelbree |
| Pfizer INC. | $16.77 | 2024 | |
| Organon LLC | $15.81 | 2025 | Nexplanon |
| Glaxosmithkline, LLC. | $15.40 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.